Edition:
India

People: Denali Therapeutics Inc (DNLI.OQ)

DNLI.OQ on NASDAQ Stock Exchange Global Select Market

18.28USD
10:35pm IST
Change (% chg)

$-0.29 (-1.56%)
Prev Close
$18.57
Open
$18.61
Day's High
$18.61
Day's Low
$17.75
Volume
17,308
Avg. Vol
137,478
52-wk High
$28.84
52-wk Low
$13.78

Tessier-Lavignec, Marc 

Dr. Marc Tessier-Lavignec is Chairman of the Board, Co-Founder of Denali Therapeutics Inc. Marc is currently President of Stanford University. Prior to his current role, Marc served as President of The Rockefeller University in New York City, where he was also Carson Family Professor and Head of the Laboratory of Brain Development and Repair. Marc has held faculty positions at the University of California, San Francisco, and Stanford University, before joining Genentech, where he served as Executive Vice President of Research and Chief Scientific Officer, overseeing the company’s disease research and drug discovery efforts. He is the recipient of numerous scientific awards, including being elected a member of the National Academy of Science and the National Academy of Medicine. Marc obtained undergraduate degrees from McGill University and Oxford University, where he was a Rhodes Scholar, and a Ph.D. in neurophysiology from University College London.

Basic Compensation

Total Annual Compensation, USD 31,707
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 601,184
Fiscal Year Total, USD 632,891

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Marc Tessier-Lavignec

632,891

Ryan Watts

1,366,860

Alexander Schuth

1,076,940

Steve Krognes

1,166,560

Dana Andersen

--

Carole Ho

1,368,000
As Of  31 Dec 2017